Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival among all patients · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival among all patients compared with primary surgery (high certainty).
1 finding from 1 review
Presence of tumor‐free resection margin · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in presence of tumor‐free resection margin compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (T0 to T2 vs T3 to T4) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to higher tumor stage at resection (T0 to T2 vs T3 to T4) compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (N0 vs N+) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy may leads to higher tumor stage at resection (N0 vs N+) compared with primary surgery (low certainty).
1 finding from 1 review
Postoperative morbidity RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Postoperative mortality RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Disease-free survival · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in disease‐free survival (landmark time 6 months) compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Esophagus · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Esophagus compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ GE junction · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by tumor site ‐ GE junction compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Stomach · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Stomach compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival (OS) · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
1 finding from 1 review
Disease-free survival · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
1 finding from 1 review
Overall survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · treatment of relapsed epithelial ovarian cancer
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).
1 finding from 1 review